ABBV- AbbVie Inc.
Healthcare · Drug Manufacturers - General
Price & Performance
Performance
Analysis & Verdict
Analyst Ratings
BuyWall Street consensus from 29 analysts
12-Month Price Target
$277.31
Based on analyst estimates; price targets are opinions, not guarantees.
Fair Value Estimates
Current price: $257.12
Graham Number
√(22.5 × EPS × Book Value)
N/A
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$98.40
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
7/10
88% score
Pays dividends
13Y hist.13+ years of dividend history
Dividend consistency (5Y+)
13 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
Return on equity - measures how efficiently capital is used
Positive profit margin
9.8%Net profit margin must be positive - company earns more than it spends
Revenue growth (annual)
+10.2%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
+290.4%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
Low financial leverage reduces risk of distress
Current ratio above 1
0.81×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.7B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.69%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Oct 29, 2026
46
days
EPS (TTM)
$3.55
P/E (TTM)
72.4
Fwd P/E
15.8
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.69%
5Y Avg Annual
$5.9020
Last Payment
$1.7300
Ex-Date
07/15/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest07/15/2026 | 07/29/2026 | $1.7300 | 2.69% |
04/15/2026 | 04/29/2026 | $1.7300 | 2.69% |
01/16/2026 | 01/30/2026 | $1.7300 | 2.69% |
10/15/2025 | 10/29/2025 | $1.6400 | 2.55% |
07/15/2025 | 07/29/2025 | $1.6400 | 2.55% |
04/15/2025 | 04/29/2025 | $1.6400 | 2.55% |
01/15/2025 | 01/29/2025 | $1.6400 | 2.55% |
10/15/2024 | 10/29/2024 | $1.5500 | 2.41% |
Magic Number
Shares needed to self-fund your next purchase
$257.12
Price
$1.7300
Last div. (quarterly)
149
shares
Own 149 ABBV shares ($38,310.88) and each quarterly dividend pays for 1 new share - the snowball runs on its own.
Investment target
$38,310.88
New shares / year
+4 shares
Dividend Calculator
2.69% yieldEstimate ABBV dividend income at the current rate.
Per year
$269.14
Per month
$22.43
≈ 38.9 shares at $6.92/share a year. Estimate only - dividends can be cut or raised.
Tools & Simulators
ABBV vs Peers, Indexes & Commodities
?Click a card below to plot it on the chart
Loading history…
Parameters
Final value
$426,404.61
Total invested
$130,000.00
Total interest
$296,404.61
Balance over time
Period breakdown
| Period | Balance | Invested | Interest |
|---|---|---|---|
| Start | $10,000.00 | $10,000.00 | $0.00 |
| Year 1 | $17,270.27 | $16,000.00 | $1,270.27 |
| Year 2 | $25,267.56 | $22,000.00 | $3,267.56 |
| Year 3 | $34,064.59 | $28,000.00 | $6,064.59 |
| Year 4 | $43,741.32 | $34,000.00 | $9,741.32 |
| Year 5 | $54,385.72 | $40,000.00 | $14,385.72 |
| Year 6 | $66,094.55 | $46,000.00 | $20,094.55 |
| Year 7 | $78,974.28 | $52,000.00 | $26,974.28 |
| Year 8 | $93,141.97 | $58,000.00 | $35,141.97 |
| Year 9 | $108,726.44 | $64,000.00 | $44,726.44 |
| Year 10 | $125,869.35 | $70,000.00 | $55,869.35 |
| Year 11 | $144,726.56 | $76,000.00 | $68,726.56 |
| Year 12 | $165,469.48 | $82,000.00 | $83,469.48 |
| Year 13 | $188,286.70 | $88,000.00 | $100,286.70 |
| Year 14 | $213,385.63 | $94,000.00 | $119,385.63 |
| Year 15 | $240,994.47 | $100,000.00 | $140,994.47 |
| Year 16 | $271,364.18 | $106,000.00 | $165,364.18 |
| Year 17 | $304,770.87 | $112,000.00 | $192,770.87 |
| Year 18 | $341,518.22 | $118,000.00 | $223,518.22 |
| Year 19 | $381,940.31 | $124,000.00 | $257,940.31 |
| Year 20 | $426,404.61 | $130,000.00 | $296,404.61 |
What is compound interest?
Compound interest means that the interest you earn in one period is added to your principal, so in the next period you earn interest on a larger base. This creates exponential growth: the longer your time horizon, the more dramatic the effect.
Which rate should I use?
The S&P 500 has historically returned ~10%/year before inflation over long periods - use this for an all-equity US index fund scenario. A balanced growth portfolio (stocks + bonds) is closer to 7%. High-yield savings accounts (HYSA) are currently paying around 4-5% with FDIC insurance and zero market risk. Bonds historically return ~4% annualized.
Formula used
FV = PV × (1+r)^n + PMT × ((1+r)^n − 1) / rwhere r is the monthly rate, n is the number of months, PV is the initial investment, and PMT is the monthly contribution. Annual rates are converted to monthly viar = (1 + annual%)^(1/12) − 1.
For educational purposes only. Not financial advice. Past returns do not guarantee future results.
Discussion
Sign in to join the discussionSign inLoading…
Discover
Related Assets
Healthcare
Related Articles
About AbbVie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
North Chicago, United States
Employees
57,000
Stock Market ROI Pro
All features, zero ads- web & app
Unlock every feature, ad-free, across our website and iOS app.
AbbVie Inc. (ABBV) stock trades at $257.12, up 0.83% on the day. With a market capitalization of $454.36 billion, ABBV is a mega-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 72.4, a forward P/E of 15.8 and earnings per share (EPS) of $3.55. Over the most recent period the company reported 10% year-over-year revenue growth and a net profit margin of 9.8%. Below you'll find ABBV's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
ABBV - Frequently Asked Questions
Is AbbVie Inc. (ABBV) a good stock to buy in 2026?
AbbVie Inc. (ABBV) shows strengths such as revenue growth of 10%, while risks include a rich P/E of 72×. Whether ABBV is a good buy in 2026 depends on your time horizon and risk tolerance - review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is ABBV's stock price today?
AbbVie Inc. (ABBV) trades at $257.12, up 0.83% on the session. Prices on this page update throughout the trading day.
Does ABBV pay a dividend?
Yes. AbbVie Inc. pays an annual dividend of $6.92 per share, a dividend yield of 2.69%. The most recent ex-dividend date was October 15, 2026. Its payout ratio is about 190% of earnings.
Is ABBV overvalued?
With a P/E ratio of 72.4×, ABBV trades at a premium valuation for the healthcare sector. Its PEG ratio is 0.53 (below 1, which can signal growth at a reasonable price). See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is ABBV's market cap?
AbbVie Inc. (ABBV) has a market capitalization of $454.36 billion, classifying it as a mega-cap stock in the Healthcare sector.
Disclaimer: This page - including any buy/hold/avoid view, fair value or price estimate - is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.